Our services

ADC Review
is made possible by:

NCT02581631/ CheckMate 436 (Clinical Trial / Brentuximab Vedotin / Adcentris®)

Study Title
A Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436) NCT02581631

Trial Description
This is a signaling study to assess whether nivolumab in combination with brentuximab vedotin is safe and effective in certain subtypes of non-hodgkin lymphomas.

This trial is sponsored by Bristol-Myers Squibb® in collaboration with Seattle Genetics®

Study Data

  • Condition: Non-Hodgkin’s Disease
  • Interventions:
  • Phase: I & II
  • Enrollment: 96
  • Start: December 2015
  • Estimated Completion: December 2018
  • Last verified: December 2016
  • Last Updated: December 2016

Study Schematic

NCT02581631/ CheckMate 436 (Clinical Trial / Brentuximab Vedotin / Adcentris®)

Click here to Return to Drug map

Last Editorial review: December 13, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Manuscript Guidelines & Tips

Skip to toolbar